ANXA3 and gastric cancer: Furthermore, a bioinformatics analysis on the genomic data of 119 fluoropyrimidine-treated gastric cancer patients reported that SNP rs2867461 in the ANXA3 gene exhibited a significant correlation with the sensitivity to fluoropyrimidine treatment and might therefore serve as a potential genetic biomarker in predicting the therapeutic response (Takahashi et al., 2015).